Adverse events308

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 308

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	5	10	7
other	Abdominal pain	Gastrointestinal disorders	All Other Patients	3	8	4
other	Activated partial thromboplastin time prolonged	Investigations	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	1	10	2
other	Activated partial thromboplastin time prolonged	Investigations	All Other Patients	0	8	0
other	Agitation	Psychiatric disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	1	10	1
other	Agitation	Psychiatric disorders	All Other Patients	0	8	0
other	Alanine aminotransferase increased	Investigations	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	5	10	20
other	Alanine aminotransferase increased	Investigations	All Other Patients	2	8	2
other	Alkaline phosphatase increased	Investigations	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	7	10	9
other	Alkaline phosphatase increased	Investigations	All Other Patients	3	8	4
other	Allergic reaction	Immune system disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	1	10	1
other	Allergic reaction	Immune system disorders	All Other Patients	0	8	0
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	2	10	2
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	All Other Patients	1	8	1
other	Anemia	Blood and lymphatic system disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	8	10	108
other	Anemia	Blood and lymphatic system disorders	All Other Patients	5	8	16
other	Anorexia	Metabolism and nutrition disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	5	10	6
other	Anorexia	Metabolism and nutrition disorders	All Other Patients	2	8	2
other	Anxiety	Psychiatric disorders	Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC	1	10	1
other	Anxiety	Psychiatric disorders	All Other Patients	0	8	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00924170/events

API reference For AI assistants

Adverse events308

Sources 3

Read this list from software.